share_log

Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $19

Benzinga ·  Dec 19 22:58  · Ratings

Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from $31 to $19.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment